Michael Andreeff

机构：The University of Texas MD Anderson Cancer Center · ORCID：0000-0002-1144-1958

发表论文 2047 篇 · 总被引 75488 次 · h-index 139

代表论文

Data from Investigational Clinical Trial Agents versus Conventional Second Salvage Therapies in Patients with Relapsed/Refractory Acute Myeloid Leukemia (2026)
Supplementary Data 1 from Investigational Clinical Trial Agents versus Conventional Second Salvage Therapies in Patients with Relapsed/Refractory Acute Myeloid Leukemia (2026)
Supplementary Materials1 from The Novel Hypomethylating Agent NTX-301 Reprograms Epigenetic and Hippo Signaling Pathways and Exhibits Preclinical Activity in Venetoclax-Resistant and TP53-Mutant AML (2026)
Supplementary Tables1 from The Novel Hypomethylating Agent NTX-301 Reprograms Epigenetic and Hippo Signaling Pathways and Exhibits Preclinical Activity in Venetoclax-Resistant and TP53-Mutant AML (2026)
Data from The Novel Hypomethylating Agent NTX-301 Reprograms Epigenetic and Hippo Signaling Pathways and Exhibits Preclinical Activity in Venetoclax-Resistant and TP53-Mutant AML (2026)
Dual MYC and GSPT1 Protein Degrader for MYC-Driven Hematologic Malignancies (2026 · Blood)